Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2025 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

Stand strong together  Editorial  Looking at current events in France, Europe, and around the world in 2025, these are uncertain, even menacing, times, as was already the case in many countries in 2024. The global consensus forged after World War II is under threat; free trade agreements that were supposed to contribute to peace and prosperity were torn up from one day to the next by the president of the very country that imposed them on the rest of the world. Full article available for download (FREE) 1 December 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Attenuated chikungunya vaccine (Ixchiq°)  Marketing Authorisations  The first chikungunya vaccine to have been authorised in the European Union is a live attenuated virus derived from a strain isolated on Reunion Island in 2006. Is this vaccine effective at preventing chikungunya infections and their complications? Does it slow transmission during an epidemic? Is it useful for travellers visiting an area where chikungunya is endemic? And what are its adverse effects? Full article available for download by subscribers 1 December 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Iptacopan (Fabhalta°) in paroxysmal nocturnal haemoglobinuria  Marketing Authorisations  Paroxysmal nocturnal haemoglobinuria is a rare, potentially fatal condition in which patients produce red blood cells that are unusually susceptible to haemolysis. Treatment is mainly based on blood transfusions and intravenous eculizumab or ravulizumab. Iptacopan has been authorised in the European Union as an oral treatment for adults with paroxysmal nocturnal haemoglobinuria with haemolytic anaemia.  Full article available for download by subscribers 1 December 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Pregnancy and "disease-modifying" drugs for multiple sclerosis: what are the consequences for the unborn child?  Adverse effects  Multiple sclerosis is a disease of the central nervous system that usually follows a relapsing-remitting course. It often affects women and generally starts between the ages of 20 and 40 years. As of 2025, what is known about the consequences for the unborn child of exposure to the main disease-modifying drugs currently authorised in France for use in pregnant women with multiple sclerosis? This article reviews the main data we identified through our literature search.  Full article available for download by subscribers 1 December 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Weekly methotrexate: evaluation of risk minimisation measures commissioned by the European Medicines Agency  Outlook  The European Medicines Agency (EMA) recently commissioned a private company to evaluate the "risk minimisation measures" it has introduced to reduce errors related to taking or injecting methotrexate at daily instead of weekly intervals. The impact of these measures was found to be modest at best.  Full article available for download by subscribers 1 December 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Fezolinetant for menopause-related hot flushes • Momelotinib in myelofibrosis • Adverse effects of nirsevimab • Methylphenidate: the youngest children in a given school year at higher risk of starting treatment > Subscribe now 1 December 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn and Facebook Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn or > Follow us on Facebook 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2025 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---